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Summary. A main goal of the industrialized world is the 
development of effective vaccines to control infectious 
diseases with major health and socio-economic impact. 
Current understanding of the immune response triggered 
during infection with pathogens causing malaria, 
hepatitis C and AIDS emphasizes the importance of 
cytotoxic T lymphocytes (CTLs) in combating these 
infections. This has led to the development of new 
vaccination strategies, some of which are in phase I/II 
clinical trials. Promising strategies of vaccination are 
based on highly attenuated vira1 vectors, such as 
Vaccinia virus (W) in combination with heterologous 
like vectors naked DNA, referred to as priming/booster 
vaccination. While these immunization schedules 
increased the production of specific CTLs, there is a 
need to further expand the CD8+T cell population to 
control an infection. Among molecules that play a 
significant role in the modulation of the CTL response is 
the cytokine IL-12. Immunoregulation by IL-12 is of 
central importance in cell-mediated immunity (CMI) 
against those pathogens and tumors that are controlled 
by cell-mediated mechanisms, supported by Thl cells. 
The use of this cytokine in combination with highly 
immunogenic W-derived vectors is a promising system 
for development of future vaccination schedules. In this 
review, we summarize recent data on the use of IL-12 in 
vaccination procedures, as well as undesired side-effects 
of the cytokine that can be overcome by accurate use of 
dose, route and time-window administration of IL-12 
encoding vectors. Results described here indicate that 
VV IL12-mediated enhancement of the specific CM1 
response against a model antigen HIV-1 env was time- 
and dose-dependent and that the antigen and the 
cytokine could be expresed from two different rVVs 
modulating the doses of the vectors and allowing for 
enhancement of a specific CM1 response. Moreover, the 
use of IL-12 during DNA prime/VV boost regimens 
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enhanced the specific anti-HIV-1 env cellular response 
20 times compared to that generated after a single 
rWenv inoculation. Variables such as: a) dose of the 
cytokine applied, b) time of its administration and c) 
routes of inoculation play a critica1 role in the final 
outcome of the response. The findings presented here 
can be extended to other antigens, suggesting that 
immunomodulatory cytokines can be useful in the 
development of the future vaccines against numerous 
infectious diseases and tumors. 
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lntroduction 
In the development of strategies for vaccination the 
main objective is the induction of the most appropriate 
type of immune response able to control pathogen 
replication. The type of immune response induced 
during an immunization is in part dependent on the types 
of CD4+ helper T cells that are generated. Two different 
subsets of CD4+ T lymphocytes, Thl and Th2, dsering 
in the pattern of cytokines produced, have been 
described to be crucial in the generation of a cellular or 
an antibody immune response respectively. Thl and Th2 
cells develop from naive CD4+ T cells, and the 
differentiation process of these cells is initiated by 
interaction of the T cell receptor with peptide antigen 
and directed by cytokines present during the initiation of 
the cell response. Within the cytokine network, IL-4 
promotes Th2 development and IL-12 plays a pivotal 
role in the development of T h l  cells from naive 
precursor T cells. T h l  cells secrete a characteristic 
pattern of cytokines (IFN-y, TNF-a and 0, IL-2) 
promoting cell-mediated immune responses, acting 
against intracellular pathogens. Th2 cells produce 
cytokines (IL-4, IL-5, IL-6, IL-10, IL-13) that are 
involved in the development of humoral immunity 
which protects against extracellular pathogens. The cell- 
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critica1 for T helper cell development and IL-12 
production. When an antigenic stimulus induces a Th2 
response different possibilities may explain this fact: the 
first one is that Th2-inducing DCs belong to a particular 
lineage, and second, there is a unique lineage of DC that 
induces T h l  or Th2 differentiation based on the 
influence of factors on the IL-12 secretion (Sinigaglia et 
al., 1999). Thus, many pathogens can control the type of 
immune response generated through the modulation of 
IL-12 production by dendritic cells. Once secreted, IL- 
12 activates the Thl-specific transcriptional program on 
T cells, activating selectively the transcription activator 
factor STAT4 (Szabo et al., 1995), and the IFN- 
regulatory factor-1 (IRF1) (Coccia et al., 1999) on Th l  
cells, which have been irnplicated in the development of 
T h l  cells. The lymphocyte response to IL-12 is 
dependent on the expression of the high affinity IL-12R, 
that has two subunits (B1 and B2). The IL-12RB2 
expression represents the main checkpoint for the 
responsiveness to IL-12 in developing T cells (Rogge et 
al., 1997; Szabo et al., 1997). Thus, in the absence of IL- 
12, IL-12RB2 is expressed at low levels but in the 
presence of IL-12, IL-12RB2 is upregulated. Thus, cells 
that develop along the Thl  pathway continue to express 
both IL-12R subunits, and there is a selective loss of the 
IL-12RB2 transcripts during differentiation of T cells 
along the Th2 pathway. In a recent report (Rogge et al., 
1999), a rnonoclonal antibody to the IL-12 receptor B2 
chain recognized T cells from patients with a Thl-type 
but not with a Th2-type inflammatory disease, 
suggesting that expression of IL-12RB2 chain might be 
considered as a marker of Thl  cells. 
Another property of IL-12 is its role in T cell 
trafficking, mediated by its ability to upregulate a subset 
of genes functionally related to leukocyte trafficking, 
thus confering a selective ability to T h l  cells to 
penetrate and localize within certain tissues for the 
immune response (Sallusto et al., 1998; Lim et al., 
1999). Overall, the main characteristic of IL-12 is to be a 
principal immunoregulatory molecule that influences the 
interaction among pathogens and the host immune 
system. 
The use of IL-12 in therapy with animal and human 
models of infectious diseases 
The ability of IL-12 to skew the immune response 
into the cellular immune arm forms the basis of its 
activity as an adjuvant in vaccinations against infectious 
diseases and cancer. In animal models of infectious 
diseases, IL-12 was first shown to be effective as a 
prophilactic agent for Leishmania major infection 
(Afonso et al., 1994). This activity was then extended to 
other intracellular pathogens such as Listeria 
monocytogenes (Miller et al., 1995) and intracellular 
parasites such as Schistosoma mansoni (Wynn et al., 
1995). In a recent study (Kenney et al., 1999),  
recombinat human IL-12 has been employed in 
conjuction with alum as adjuvants with killed antigen in 
a primate model of cutaneous leishmaniasis. Prornising 
results were obtained providing a basis for further use in 
clinical human trials. The IL-12 benefits as adjuvant 
have also been employed in both systemic (Operschall et 
al., 1999) and intranasal (Arulanandam et al., 1999) 
administrations during imrnunization of mice against 
viral infections such as respiratory syncitial virus (Tang 
and Ghaham, 1995), pseudorabies virus (Schijns et al., 
1995), and influenza virus (Arulanandam et al., 1999). 
Several studies have evaluated the IL-12 capacity to 
enhance the specific CM1 against HIV-1. Thus, during 
immunization strategies based on DNA, the 
coadministration of plasmids encoding IL-12 plus HIV-1 
antigens increased both the specific CTL and T h l  
proliferative responses (Takashi et al., 1997; Kim et al., 
1998). In other studies, IL-12 has been shown to act 
sinergistically with GM-CSF and TNF-a (Okada et al., 
1997; Takashi et al., 1997), in the enhancement of 
specific CTL against HIV-1 antigens. The cytokine has 
also been administered from viral vectors in conjunction 
with desired antigens and is the subject of discussion in 
the next section. 
Finally, a number of studies performed in various 
animal models addressed the potent antitumor effects of 
IL-12. Administration of IL-12 showed a therapeutic 
effect controlling growth of primary and metastatic 
tumors at non-toxic doses (Rodolfo and Colombo, 
1999). The use of IL-12 as a candidate adjuvant for 
vaccination against cancer is under consideration by a 
number of laboratories. However, the adverse toxic 
effects in humans have hampered its further 
development into clinical applications. The first reported 
trial in which adverse effects were observed was during 
Phase 11 studies conducted by the Genetics Institute of 
Cambridge (Cohen, 1995). In this study 17 patients with 
renal cell carcinoma that received the cytokine showed 
sympthoms of toxicity that affected multiple organs, and 
two of the treated patients died. In other clinical trials 
the cytokine was well tolerated when minor doses of IL- 
1 2  were subcutaneously administered instead of 
intravenously (Lamont and Adorini, 1996). Later, it was 
shown in murine and primate models that pretreatment 
with a single injection of IL-12 before the administration 
of a daily IL-12 regime protected the animals from the 
toxic effects, a fact that was associated with minor IL12- 
driven IFN-y levels. However in some studies it was 
shown that while the predosing approach desensitizes 
animals to the toxic effects, it can also compromise the 
IL-12 therapeutic benefits (Coughlin et al., 1997). Gene 
therapy may be a suitable option to overcome toxicity 
effects, and this approach was employed in several 
animal models and in clinical protocols (Rodolfo and 
Colombo, 1999). In a Phase 1 clinical study with 
melanoma metastasic patients,  vaccination with 
autologous IL-12 gene modified tumor cells, and 
induced immunological changes leading to an increased 
antitumor imrnune response (Sun et al., 1998). 
Other non-desired side effects associated with IL-12 
administration were potential immunnosuppresive 
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actions. Indeed, transient IL-12 suppression of the 
immune response was observed in severa1 murine 
models when administered exogenously as a soluble 
product (Kurzawa et al., 1998) or when expressed from 
vectors (Lasarte et al., 1999). This suppressive effect 
appears to be mediated by the nitric oxide (NO) 
generated from activated macrophages (Kurzawa et al., 
1998). 
Another potential use of IL-12 is associated with 
immune restoration on HIV-1-infected individuals 
during immuno-therapy treatment. Data generated from 
different laboratories (Clerici et al., 1993; Chechimi et 
al., 1994), suggest that a shift from Thl to Th2 may be 
associated with a decline in the clinical status of HIV-1- 
infected patients. Thus, studies with PBMC from HIV-1- 
infected patients revealed an impairment in the 
production of IL-12 against different stimuli when 
compared to healthy donors, suggesting that a primary 
I L 1 2  defect may lead to secondary deficiencies, and in 
turn amplify the immunodeficiency during HIV-1 
infection (Marshall et al., 1999). In addition, a direct role 
of IL-12 in controlling HIV-1 replication on T cell 
clones has been reported (Salgame et al., 1998). 
However, while administration of recombinant human 
IL-12 to chronicaiiy SIVmac-infected rhesus monkeys 
was well tolerated, it did not cause reduction in virus 
load of the infected animals (Watanabe et al., 1998). 
This  controversy limited the use of IL-12 as a 
therapeutic agent to restore immune parameters in HIV-1 
immunosuppressed individuals. 
IL-12 expressed from r W  as an attenuated model 
vector for the delivery of cytokines 
Studies on live-based vectors represent a promising 
target area of vaccine research. Probably the best studied 
vector is vaccinia virus (VV), the prototype member of 
the Pomirus family, that was succesfully used as a live 
vaccine to erradicate smallpox (WHO, 1980). This virus 
represents a good candidate for vaccination purposes 
because of its broad host range and the ability to 
generate recombinant viruses (rVV) that express a 
Flg. 2. A. Scheme of the rW genomes. The genes wding for luciferase (Luc) and HIV -1 Env (Env) proteins were inserted into the thymidine kinase 
(TK) locus of the W genome. The DNA cassette containing the genes coding for 11-12 was inserted into the HA locus to generate the double 
recombinants, rWuc 11-12 and rWenvlL-12. P11, p7.5 and e/l represent diierent W promoters. B. Expression of IL-12 by r W  severely compromises 
virus replication in mice. BALBIc mice were inoculated ¡.p. with 5x107 PFUIanimal of W u c  HA- or NWuc 11-12, and ovaries and spleens were 
collected on the indicated days. Luciferase acüvity in the different homogenate tissue samples was measured, and values were related to the amount of 
protein present in tissue extracts (relative luciferase units (RLU) per milligrams of protein). Background levels found in control uninfected tissues were 3 
and 4 IoglO RLU per milligrams of protein for spleen and ovaries, respectively. Results represent mean values (with the SD) from samples of three 
animals per day and group. C. Kinetics of 11-12 and lFNy expression following inoculation of mice with rWluc 11-12. Groups of mice were inoculated 
¡.p. with 5x107 PFU/animai of rWlucHA- (open symbols or rWluclL-12 (filled symbols), and at the indicated time points sera and spleens were obtained 
from three mice per group. In the upper pannel serum levels of lFNy and IL-12 were evaiuated (by ELlSA and bioassay respectively). In the lower 
pannel levels of 11-72 and lFNy mRNA in spleens were determined by RT-PCR. The expected sizes of the PCR products are indicated. Levels of 
HPRT mRNA were uaed as an interna1 control. 
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variety of foreign antigens (Moss, 1996). Recombinant 
VV vectors have also been proven effective in field 
animal vaccination programs (Brochier et al., 1995). 
When r W  were tested in different vaccination schedules 
on simian hosts, specific cellular and humoral immunity, 
both systemic (Hirsch et al., 1996) or mucosa1 (Belyakov 
et al., 1998) were elicited. The above findings suggest 
that VV-based vaccination approaches using highly 
attenuated strains might be a promising prophylactic 
strategy against severa1 infectious agents of world-wide 
health importance. In our laboratory we are interested in 
evaluating the effectiveness of the use of rVV as live- 
based viral vectors that could contribute to the 
development of safe vaccines against pathogens like 
Plasmodium, Leishmania and HIV-1 to whose protection 
relies on CM1 responses. 
In the case of HIV-1, the scope of our approaches are 
directed to enhance the specific CM1 response against 
the HIV-1 env gene product, either by the delivery of IL- 
12 and gp160 (env) from rVV, or by the application of 
bimodal immunization schedules that exploit the 
boosting capacity of rVVs on heterologous primed CTL 
responses (particularly in DNA prime/VV boost 
regimens) in combination with IL-12 delivery from 
DNA. We have generated (Fig. 2A) double rVVs 
expressing the murine IL-12 subunits p35 and p40 in an 
expression cassette using the EMCV IRES strategy, 
inserted in the hemagglutinin locus of the Western 
Reserve (WR) strain of VV and the clade B HIV-1 env 
gene from the IIIB strain or the luciferase reporter gene 
inserted in the thymidine kinase viral locus (rWenvIL- 
12 and rVVlucIL-12, respectively). Following systemic 
inoculation of susceptible BALBIc mice with a high 
dose of rVVluc IL12, a marked attenuation of the virus 
occurs, as indicated by a more rapid kinetic of virus 
clearance from target tissues and lower peak viral titres 
than in mice infected with control HA- r W  that do not 
express the cytokine (Fig. 2B). Serum and spleen levels 
of IL-12 after rWenvIL12 inoculation were five times 
higher than during a control VV infection. These 
differences were directly correlated with the IFN-y levels 
in rWenvIL12 mice (Fig. 2C). Importantly, the specific 
immune response against vector-derived antigens or to 
the HIV-1 gp160 was skewed to a Thl  type as revealed 
by the IgG2aflgGl ratio, the number of specific CD8+ 
T-cells and the profile of cytokines secreted during T-cell 
restimulation (IFN-y vs. IL4 levels) (Fig. 3). However, 
the magnitude of these responses was lowered with 
increased doses of the rWenvIL-12 used and such effect 
correlated with higher IFN-y serum levels at shorter 
times post-inoculation (12 hpi) in mice irnmunized with 
high doses of the virus (Fig. 4). These findings indicate 
that the IL-12-mediated enhancement of the specific 
CM1 response against the HIV-1 env product was dose- 
dependent, a result of relevance in further uses of IL-12. 
Such undesired property exerted at high doses of I L 1 2  
has been adressed in other experimental models 
following viral infection with LCMV or MCMV upon 
administration of recombinant mIL-12 and seems to be 
associated with IFN-y-driven NO induction (see below). 
Moreover, our exploration on the optimal conditions of 
IL-12 delivery in mice using rVVs indicated that a 
profitable strategy is to express the specific antigen (the 
HIV-1 env gene) and the cytokine from two different 
Fig. 3. lmmune response induced against W antigens 14 days afier ¡.p. inoculation with 5 x107 PFUIanimal of rWlucHA- or rWluclL-12. A. Serum- 
specific anti-vaccinia lgG2aJlgGl ratio. Anti-vaccinia IgG antibodies were determined by ELlSA and titers calculated as the log2 dilution that gave an 
absorbance at 492 nm >0.1 O.D. B. Determination by the ELISPOT assay of the number of the IFN-y-secreting CD8+ T cells specific for W Ags. 
Spleen cells were employed as responder cells in the ELISPOT assay using P815 cells infected with W as targets. Data are representative of at least 
two independent experiments each in triplicate. C. Pattern of cytokine secretion in supernatants of spleen cells after Ag restimulation. Splenocytes were 
cultured with in vitro with W Ag (UV inactivated) at 1 pg/ml, and supernatants were collected and cytokines determined at 48 hs (IL-10) or 72 hs (IFN-y) 
by ELISA. Three different experiments were conducted and the results of one representative experiment are shown. 
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r W s .  We found that by this approach it is easier to find 
the combination of viral doses that generate better 
specific CM1 responses. In our particular system it 
appears that when a low dose ( 2 x 1 0 ~  pfulmice) of 
rVVIL-12 is combined with a moderate dose ( lx lo7  
pfulmice) of rWenv, nearly a three-fold increase in the 
number of specific anti-gpl60 CD8+ T-cells can be 
raised in comparison with immunization with higher 
doses of either rWenv or rWenvIGl2.  (Fig. 5). 
The primelboost aproach as a new vaccinatlon 
strategy 
Recombinant W expressing particular antigens has 
proven to promote an expansion of specific CD8+ T- 
cells when administered as a boost after a prime given 
with either recombinant proteins, VLP, non-related viral 
vectors (influenza virus, Semliki Forest virus, Sindbis 
virus) or DNA vectors (Kent et al., 1998; Hanke et al., 
1999). This primeboost approach to enhance specific 
CD8+T cells was first documented in a malaria mouse 
model (Miyahira et al., 1998) and thereafter it has been 
shown to be effective in raising protection against 
malaria and SIV infection in murine (Scheneider et al., 
1998) and primate non-human models (Robinson et al., 
1999) respectively. 
Although underlying immune phenomena of this 
property of W is still elusive, it is currently accepted 
that during the primeboost approach, a moderate CD8+ 
T-cell response is  primarily induced against a few 
epitopes after priming, particularly with DNA 
immunizations, using a single antigen. A boost with an 
rVV expressing the same antigen allows expansion of 
the CD8+T cell population, and although the W boost 
also primes naive W-specific immune cells, the already 
primed antigen-specific memory T-cells can react faster 
and therefore expand rapidly (Fig. 6) 
DNA and W antigen delivery systems are suitable 
vaccine vectors due to their ability to elicit both humoral 
and cell-mediated immune responses; both vectors 
nonetheless have limitations in practica1 applications due 
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Flg. 4. Enhancement oi specific iclular immune response against the 
HIV-1 Env protein is dependent on the viral dose of rWenvlL-12. 
A. Data represents the number of 1FN-y- secreting CD8+T cells specific 
for the V3 loop epitope of the HIV-1 Env protein. Splenocytes from four 
mice immunized ¡.p. with the indicated dose of the rWenvHA- or 
WVenvlL-12 were p d e d  14 days aíter immunization, and the number 
of specific 1FN-y-secreting CD8+T cells was determined aíter coculture 
with P815 cells coated with the specific peptide (9 aa of the V3 loop of 
the HIV ll lB Env protein) by ELISPOT assay. Bars represent the 
mean*SD for triplicate cultures. B. Data represent IL-12 and IFN-y 
serum levels at 12 h postinoculation at the indicated doses. Pooled sera 
from four mice inoculated in each case were used to measure 11-12 or 
IFN-y by bioassay or ELISA, respectively. Results are the mean~SD of 
triplicate measurements. 
Fig. 5. A cornbined immunization scheme improved the IL-12-mediated 
enhancement of the cellular immune response against the HIV-1 Env 
Ag. Numbers of IFN-y-secreting CD8+T cells specific for the V3 loop 
epitope oi the HIV-1 Env protein are shown. Splenocytes from four mice 
immunized with the indicated doses of the rWenv or rWIL-12 viruses 
were pooled 14 days aíter immunization, and the number of specific 
IFN-y-secreting CD8+T cells was determined by EUSPOT assay aíter 
coculture with P815 cells coated with the specific peptide (9 Env). Bars 
represent the meaniSD for triplicate cultures. In the insetl the relative 
stimulation index and levels of IFN-y in supernatants from cultures of 
splenocytes from the different immunized groups of mice is shown. 
Fourteen days after immunization splenocytes from the different 
indicated groups were tested for T cell prolieration by stimulation with 
either gp160 protein (1 pg/ml) or medium (negat~e control). To the leít, 
the graph represents the relative specific T cell proliferative response 
against gp160, calculated as relative stimulation index [counts per 
minute in the combined immunization grouplcounts per minute in the 
control group (rWenvHA-)]. On the right are the levels of IFN-y in 
supernatants 
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to weak responses in single immunizations with DNA 
vaccines (Boyer et al., 1997; Donnelly et al, 1997) and 
strong immune responses against the viral antigens 
during VV infections, which diminish the efficacy of 
repeated booster immunizations with the same vector 
(Kunding et al., 1993). To circumvent these difficulties, 
vaccination schedules based on combined prime-boost 
regimens using different vector systems to deliver the 
desired antigen appear to be a successful alternative, as 
well as the use of attenuated VV strains, like MVA 
(Scheneider et al., 1999; Ramírez et al., 2000a,b). In 
fact, recent approaches (Hanke et al., 1998, 1999; Kent 
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Ftg. 6. Schematic representation of the mechanism operating during the 
prime-boost vaccination strategy. A. Priming with an r W  vector induces 
W-specific cells T l  and T2 (CD4 and CD8 T cells) (white cells) and 
recombinant antigen-specific T1 and T2 cells (grey cells). Boosting 
(second immunization) with the same viral vector boosts both Ag- 
specific and W-specific responses at the same level. B. Priming with a 
DNA vector (piasmid) induces a moderate but focused immune 
response (both T1 and T2 type of cells) against the delivered anügen. 
During the boosting with an r W  this population of memory cells reacts 
rapidly expanding the Ag-speciiic population immune cells. C. If during 
the prirning of the imrnune response a DNA vector codiiing for a T1- 
type cytokine like 11-12 is applied, the immune response induced can be 
biased to a type 1 response. Aíter the boosting with an r W  amplification 
of the primary Ag-specific TI  response occurs, resulting in a significant 
enhancement of the number of specific T1 cells obtained alter the 
vaccination protocol. 
et al., 1998; Sedegah et al., 1998; Caver et al., 1999; 
Robinson et al., 1999) in HIV-1, SIV and malaria models 
found that a DNA prime1VV boost regimen is a very 
efficient procedure to elicit an enhanced CM1 response 
against the specific antigen and protection in murine and 
primate non-human models. 
lmprovements of the immunization regimen when 
combined with the delivery of cytokines 
The use of immunomodulators during DNA 
immunization procedures as a way to further improve 
the CM1 has been established by diffferent approaches. 
Thus, cytokines (Xiang and Ertl, 1995) and other 
molecules involved in co-stimulation signaling (Kim et 
al., 1998) expressed during DNA immunization act as 
adjuvants modulating the specific immune responses. 
For example, co-expression of I L 2  or GM-CSF with the 
antigen in a DNA vector enhances the specific humoral 
response (Chow et al., 1997; Sin et al., 1997) and DNA 
immunization strategies against HIV-1 antigens 
expressed together with GM-CSF and TNF-a improve 
specific CTL responses (Ahlers et al., 1997; Okada et 
al., 1997; Takashi et al., 1997). Indeed, other T h l  
cytokines, such as IL-15 and IL-18 have also been co- 
administered with HIV-1 antigens from DNA vectors in 
mouse models, and have proven efficient adjuvants to 
modulate the specific CM1 (Xin et al., 1999; Kremer et 
al., 1999). 
IL-12 as an adjuvant in prime-booster vaccination 
strategies 
As mentioned previously, IL12 biological functions 
that promote the generation of specific CM1 have been 
exploited successfully by both DNA and VV 
immunization schedules (Ahlers et al., 1997; Okada et 
al., 1997; Takashi et al., 1997; Kim et al., 1998; Gherardi 
et al., 1999). Our findings with rWenvIL-12 prompted 
us to study the conditions of efficient use of IL-12 
delivery in DNA prime/VV boost bimodal 
immunizations. The application of an immunomodulator 
like IL-12 during these vaccination approaches, has the 
advantage of directing the immune response to a Thl 
type of response during the generation of the specific 
immune response that occurs during the priming (Fig. 6). 
We adressed the factors that might influence the 
final outcome of the specific anti-HIV-1 gp160 immune 
response during this immunization scheme. We. focused 
our investigation to determining both the appropriate 
moment and dose of administration of IL-12 during 
bimodal immunizations in comparison with single 
immunization schedules in which either r W  or DNA 
vectors were employed. Our findings indicate (Fig. 7A) 
that expression of IL-12 by DNA vaccine (penv and pIL- 
12) during the generation of the primary immune 
response, followed by rWenv boost increases by 2-fold 
the number of specific anti-gpl6O CD8+ T-ceils raised 
when the cytokine is  not present during bimodal 
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IL-12 doses are initiated by the induction of IFN-y 
production by lymphocytes. Sufficiently high IFN-y 
levels promote the induction of iNOS activity by 
activated macrophages, generating levels of NO that 
impair T-cell proliferation. This impairment may result 
from a NO-specific inhibition of JAK2 and JAK3 
kinases or by a disruption of the JAWStatS signaling 
pathway (Bissinger et al., 1998; Duhé et al., 1998). 
These previous observations led us to propose that the 
immunosuppressive action of IL-12 when administered 
via rVV in the booster might be NO-mediated. To 
address this, we studied the effects on the CM1 response 
against HIV-1 env when the reversible inhibitor of the 
iNOS, L-NAME, was administered during the booster. 
We observed that when the drug  was inoculated 
simultaneously with rVVs, an enhancement in the 
number of anti-HIV-1 env CD8+ T-cells was detected, 
restoring the response obsewed in the control (Fig. 8, 
left). The nature of these effects was transient since at 40 
days after the last immunization no main differences 
were obsewed with respect to control immunized mice 
(with no cytokine delivered at boost) (Fig. 8, right). 
These results concur with previous studies (Kurzawa et 
al., 1998) showing transient immunosuppression 
mediated by soluble rIL-12 in a murine model of 
vaccination against tumour cells. 
I I I I  J. 
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Flg. 8. The inhibitory efífects of 11-12 delivered at booster are reversed 
by the ¡NOS inhibitor L-NAME. A scheme sumrnarizing the immunization 
procedure is shown. Three mice per group were primed ¡.d. with a 
mixture of 50 pg/plasmid per mouse of penv + plL-12 and boosted ¡.v. 
14 days later with 1x107 PFU of rWenv and the indicated amount of 
rWIL-12. At this time and for the next three days, the animals received 
a dose of 200 pg  (days O, 1 and 2) or 400 pg (day 3) of the ¡NOS 
inhibior L-NAME ¡.p. (filled bars) in 200 p1 of PBS or were left untreated 
(open bars). Fourteen (left panel) or 40 days (right panel) after boost, an 
ELISPOT assay was perforrned to determine the number of HIV-1 
gpl60-IFN-y-secreting cells. Significant difíerences: *, pe0.0005; **, 
pe0.005; *, pe0.01, with respect to the corresponding group not treated 
with inhibitor. Bars indicate the rneaniSD for triplicate cultures. 
In conclusion, our findings (Gherardi et al., 2000) 
established that the bimodal DNA prime/VV boost 
immunization regimen has the capacity to enhance the 
specific anti-HIV-1 env response almost ten times when 
compared with a single immunization with a rWenv and 
that if the IL-12 expression vector is  properly 
administered, in both the dose and route and more 
importantly in a precise time window during the 
immunizing schedule, a 20-fold increase in the number 
of env-specific CD8+ T-cells can be raised when 
compared with a rWenv inoculation (Fig. 9). 
Future prospects 
While primelbooster combination i s  gaining 
acceptance in the vaccine field and severa1 phase 1 
clinical trials for AiDS and malaria are underway, it is 
likely that as knowledge is obtained in the optimal use of 
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Flg. 9. Enhancement of specific HIV-1 env IFN- y-secreting cells as a 
function of protocols of immunization. The diagrarn represents the fold 
increase in the nurnber of anti-env-specific IFN-y-secreting CD8+ T-cells 
generated after the indicated immunization schedules. Values were 
obtained cornparing the data from at least three immunized mice in 
duplicate experiments. The number of anti-env specific IFNy-secreting 
CD8+ T-cells raised during the bimodal DNAIVV prime/boost is 
arbirarily considered as 1 and used to calculate the other values. The 
figure ernphazises the effect of the presence of IL-12 derivered in the 
priming as well the positive effect in the final outcome of the imrnune 
response measured by optimizing the route of both r W  and DNA 
vaccine inoculation (¡.p., intraperitoneal; ¡.m., intrarnuscular; ¡.v., 
intravenous). The enhancement obtained in our studies by varying the 
dose of DNA injected and the optirnal condiions for r W  delivery of IL- 
12 are ommited. lmmunization procedure was as follows: a priming 
inoculation with 50 pg of each plasmid/rnouse was followed fourteen 
days later by a boosting inoculation with 1x107 PFUlrnouse of rWenv. 
Single immunized mice were inoculated with either 1x107 PFU/mouse of 
rWenv or with 1x107 PFU of rWenv and 2x104 PFU of WlL-12 per 
mouse. The measurernent of the nurnber of specific IFNy-secreting 
cells was made by an ELISPOT assay two weeks after the last 
inoculation. 
Cytokines as adjuvants during prime-boost vaccination regimens 
cytokines to enhance specific CM1 to antigens with 
protective efficacies, the next generation of vaccines will 
include selected cytokines (L12, b 1 8 ,  GM-CSF, IFN-y, 
IL-15) in the vaccination protocols. In view of this 
likelihood, it will be necessary to expand our current 
understanding of the co-delivery of cytokines as adjuvants. 
This review highlights the notion that immuno- 
modulators, like IL-12, can be efficiently used during 
prime/boost immunization regimens based on rVV. For 
optimal benefit it is extremely important to take into 
consideration the main parameters that compromise the 
success of this approach. For many diseases, the number 
of CTLs during vaccination appears to be an index of the 
protective status. Our results clearly show that factors 
involved in such responses can improve quantitatively 
the specific CM1 raised when IL-12 was used. Variables 
like dose of the cytokine applied, time of its 
administration and routes of inoculation play a critical 
role in the final outcome of the response. Thus, these 
parameters must be considered and assayed in different 
animal-models during the different developmental 
phases of the vaccination process applied to particular 
combinations of antigens and cytokines. 
A difficulty in achieving protection against 
infectious diseases transmitted by the mucosal route, like 
HIV-1, is to induce an efficient specific response of 
antibodies and CTLs at the mucosal entry sites of the 
virus. Thus, further approaches should be undertaken to 
improve results presented here in terms of induction of 
mucosal immunity in combination with more attenuated 
VV strains. In this respect, IL-12 has been used as an 
adjuvant for mucosai immunity (Boyaka et al., 1999) 
and MVA has been shown to be a more efficient 
boosting agent than WR-VV (Ramirez et al., 2000b). 
Future prime/booster immunizations should explore the 
mucosal route for induction of CM1 and protection 
against challenge in animal models. Another approach to 
be considered is the synergistic action of IL-12 and IL- 
18. In this case, it has been demonstrated that when both 
cytokines are combined, high levels of IFN-y are 
induced (Okamura et  al., 1995). IL-18 has also 
potentiated IL-12-driven Thl  development in BALB/c 
mice (Robinson et al., 1997). Moreover, a previous 
study in a mouse model of allergic asthma showed a 
synergistic action of these cytokines in preventing a 
Th2 development (Hofstra et al., 1998), and recent 
work has shown that rIL-18 can potentiate the IL-12 
driving induction of an antigen-specific Thl  response 
against a recombinant antigen (Eberl et al., 2000). 
Delivering both cytokines from rVV might provide a 
synergistic action on the pr~tective effects against the 
virus, which might be associated with a higher specific 
CTL response against vira1 antigens. It is tempting to 
speculate that similar results might be obtained against 
recombinant antigens expressed from VV. 
In summary, here we have discussed some of the 
multiple applications of the cytokine IL12, specially its 
use as an adjuvant. The DNANV prirne/boost approach 
has been succesfully applied in different experimental 
models, proving to be an efficient strategy to enhance 
induction of specific CD8+T cells. Importantly, our 
experiments showed that this approach can be improved 
by applying cytokines that act as immunomodulators 
during the priming of the immune response. The prime- 
booster approach might be extended to other cytokines 
and antigens as part of a vaccination regimen against a 
wide range of pathogens and tumors. In al1 cases, critical 
parameters such as: a) dose of the cytokine, b)time of 
delivery, and c) route of administration, together with the 
antigen, should be characterised for each disease. 
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